Revvity (NYSE:RVTY) Updates FY 2025 Earnings Guidance

Revvity (NYSE:RVTY - Get Free Report) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided earnings per share guidance of 4.900-5.000 for the period, compared to the consensus earnings per share estimate of 4.940. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Revvity Stock Performance

NYSE RVTY traded down $0.48 on Thursday, hitting $92.95. 1,725,208 shares of the company traded hands, compared to its average volume of 929,647. The company has a market capitalization of $11.17 billion, a price-to-earnings ratio of 42.06, a P/E/G ratio of 3.82 and a beta of 1.07. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. The business's 50 day moving average price is $103.67 and its 200-day moving average price is $112.54. Revvity has a 52-week low of $88.53 and a 52-week high of $129.50.

Revvity (NYSE:RVTY - Get Free Report) last released its earnings results on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The company had revenue of $664.76 million for the quarter, compared to the consensus estimate of $662.30 million. During the same period in the previous year, the business earned $0.98 earnings per share. Revvity's quarterly revenue was up 2.3% compared to the same quarter last year. Equities analysts expect that Revvity will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be given a $0.07 dividend. The ex-dividend date is Friday, July 18th. This represents a $0.28 annualized dividend and a dividend yield of 0.30%. Revvity's payout ratio is 11.91%.

Analyst Ratings Changes

RVTY has been the topic of several research analyst reports. Raymond James restated an "outperform" rating and issued a $120.00 price objective (down from $145.00) on shares of Revvity in a research report on Tuesday. Wells Fargo & Company lowered their price objective on Revvity from $130.00 to $102.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. KeyCorp boosted their target price on Revvity from $132.00 to $145.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. JPMorgan Chase & Co. decreased their target price on Revvity from $120.00 to $100.00 and set a "neutral" rating on the stock in a research report on Tuesday. Finally, The Goldman Sachs Group decreased their target price on Revvity from $140.00 to $125.00 and set a "buy" rating on the stock in a research report on Tuesday. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $125.64.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.